Joe Jimenez, CEO of Novartis and EFPIA president talks about why the acceleration towards an outcomes-based healthcare system is so important to Europe, and to the reputation of the pharmaceutical industry.
It is "very frustrating for my industry to see all of the incredible innovation that is coming to market and not reach European patients, or patients in general where healthcare systems are under pressure," says Joe Jimenez, talking exclusively to Scrip at the European Federation of Pharmaceutical Industries and Associations' (EFPIA) annual conference.
EFPIA's outcomes-driven message is centered on the idea of improving health in a holistic and evidence-based way by evolving healthcare...
With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.
Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.
The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.
